“an increasing trend”

For PD patients, an increasing trend of the daily peritoneal ultrafiltration (UF) was observed after SV treatment [median, IQR: 400 (200–500) vs. 500 (200–850), p = 0.114] compared to the control group [median, IQR: 450 (128–762) vs. 475 (300–800), p = 0.477].

Compared with group RF, the incidence of hypotension showed an increasing trend in the restrictive group (5 versus 1, P = 0.118), though this trend was not clinically significant (Table 4 ).

Compared with the normal group, the diaphragm dysfunction group presented an increasing trend ( p = 0.119, p = 0.073) in the postoperative ICU or hospital stay.

337.84±21.49 μL, p < 0.01); however, the pBOO+USCs group exhibited an increasing trend and finally demonstrated similar voided volume as the control group in the 19 th week (340.75±16.93 vs. 316.51±16.23 μL, respectively, p = 0.119) (Fig. 1E ).

Self-esteem showed an increasing trend from 30.14 (SD 4.21) to 31.92 (SD 4.38) ( p = 0.120).

Incidence among males aged 15–19 years shifted in 2010 from an increasing trend (APC from 2006 to 2010 = 27.0; P = 0.12) to a decreasing trend (APC from 2010 to 2014 = −14.3; P = 0.25), although neither segment was significant ( Table 2 , Fig. 1 ).

Pomegranate extract (PE) supplementation led to the augmentation of circulating propionate levels ( p = 0.02) and an increasing trend for acetate levels ( p = 0.12).

The proportion of morning stiffness ( p = 0.015), joint deformity ( p = 0.015), and interstitial lung disease (ILD) ( p = 0.001) in ACPA + RA patients was significantly higher than in ACPA - RA patients, and disease activity score using 28 joint counts (DAS28)-ESR (3) also showed an increasing trend ( p = 0.120).

Since respiration declined more than growth, CUE exhibited an increasing trend ( F = 2.6, p = 0.12), rising from 0.22 in the control to 0.27 in the OTC treatment (Figure 6C ).

7.1 months, p = 0.002) and showed an increasing trend in OS (16.9 vs. 11.3 months, p = 0.12).

However, there was a significant decrease in CD31 expression and an increase of the non‐endothelial marker CD45 combined with an increasing trend in CD14 ( P = .1201) when groups 1 and 3 are compared.

Despite the lack of a significant difference, SMR showed an increasing trend as the dark phase increased (high density: F 2,33 = 2.249, p = 0.121; low density: F 2,33 = 3.031, p = 0.062, Figure 4 ).

Total protein content in BALF showed an increasing trend toward the PGD group [2.0 (1.8–10.0) mg/mL in the PGD group, 2.2 (1.2–5.9) mg/mL in the non-PGD group, p = 0.1213, Figure 6A ].

After treatment, compared to the VPA group, the number of times of standing upright of the BDNFp group was significantly increased, and the FUS + BDNFp-CMBs group showed an increasing trend ( p = 0.1227).

PK remained the primary surgical approach for repeat corneal transplants, while the proportion of EK showed an increasing trend (r = 0.520, P = 0.123; Fig. 1 ), and DALK showed a decreasing trend (r = −0.415, P = 0.233).

The pooled analysis revealed a statistically significant improvement in Bio-C bond strength with sonic activation ( p = 0.026), while AH Plus showed an increasing trend that did not reach significance ( p = 0.124).

Although not statistically significant, ECV values showed an increasing trend across T stages: 25.8 ± 5.9 % in T1, 42.1 ± 3.0 % in T2, and 40.6 ± 4.1 % in T3 tumors (p = 0.125).

6C ), whereas TF expression (1.19±0.22-fold variation to control) showed an increasing trend in the unilateral varicocele group (p=0.1257) ( Fig. 6B ) .

Results After 3 months of intervention, blood samples of 17 participants were collected and following results were reported (1) percentage of CD34+ cells increased significantly after 3 months of CYP practice (from 18.18±7.32 cells/μL to 42.48±18.83 cells/μL) (effect size: W, 0.40; 95% CI, p = 0.001) (2) neurogenesis marker, ie, BDNF showed a significant change with time after 3 months of CYP intervention (effect size: W, 0.431, 95% CI; p = 0.002), (3) HDL showed an increasing trend (non-significant) after three months of CYP practice (53.017±1.28 mg/dl to 63.94±5.66 mg/dl) (effect size: W, 0.122; 95% CI; p = 0.126) (4) General Health score (10.64 ± 3.53 to 6.52 ± 3.12) (effect size: d, 0.98; 95% CI; p = 0.001) along with visual and executive function improved (69.94±26.21 to

2 C), while the myofibroblast marker, ACTA2 , which encodes alpha smooth muscle actin (αSMA), showed an increasing trend that did not achieve statistical significance (1.24 ± 0.13-fold; P = 0.1263) (Fig. 2 D).

In M1 macrophages, lactate levels follow an increasing trend ( p = 0.128), which is also in line with the HP results.

Similarly, we failed to observe statistical significance in any of these categories, despite the overall HT showing an increasing trend in hs‐cTnT elevated patients (13.8% vs 7.4%, P = .128, OR 2.016, 95% CI 0.817‐4.969, Table 2 ). 3.3.

Moreover, in the current study, the proportion of patients treated with induction chemotherapy in LARC showed an increasing trend (44% vs. 60%, p = 0.129), in part due to MEND-IT trial investigating the benefit of FOLFOXIRI induction chemotherapy in LARC [ 24 ].

The GAG content of AuC and 1:1 discs displayed an increasing trend with time, although no statistical difference was observed between 1 and 3 months ( P = 0.13).

Cspg4 mRNA levels showed an increasing trend after 4 days of rhC3 treatment ( P = 0.13), and Mog mRNA levels were significantly reduced in rhC3-treated group ( P = 0.044).